AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03306589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: 0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
Study NCT03306589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor
Description: 5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
Study NCT03306589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: 0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
Study NCT04226053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenting, Child Development
Description: The treatment group will consist of mothers that were randomly selected to receive Room to Grow services, which include three years of social and practical support for the mother and baby. The research-informed program model combines tailored, one-on-one sessions with an expert clinical social worker in-person every three months, provision of essential baby items including books, toys, clothing, and equipment (retail value of in-kind items over three years averages $10,000), and connections to vital community resources (e.g., housing, entitlements, child care, social services).
Study NCT00965887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK0974 Ethanolate formulation
Description: Single dose MK0974 280 mg tablet in one of two treatment periods
Study NCT00965887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: MK0974 Hydrate formulation
Description: Single dose MK0974 280 mg tablet in one of two treatment periods
Study NCT03565380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated asymptomatic controls
Description: No intervention will be provided
Study NCT03325374 — intervention group
Intervention type: OTHER
Intervention: Questionnaires and examination
Description: Patients with in the BLB patients study will have interview and questionnaire carried out.
Study NCT02292563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopist only
Description: Only Colonosopist Observe during Colonoscopy (single observer)
Study NCT02292563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experienced Endoscopy Nurse Participation
Description: Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 800 mg
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 800 mg
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 800 mg
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 2000 mg
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 2000 mg
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 2000 mg
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg
Study NCT00920491 — intervention group
Intervention type: BIOLOGICAL
Intervention: biomarker-enhanced disposition decision with proADM
Description: To compare the outcome of standard of care with an approach combining the standardized course and biomarker levels (biomarker-enhanced disposition decision with proADM) for the disposition of patients with non-specific complaints presenting to the emergency department (ED), in order to evaluate safety.
Study NCT00770731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torisel (Temsirolimus)
Description: Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
Study NCT01850134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Study Product
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin 400 mg
Study NCT00770731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hycamtin (Topotecan)
Description: Starting Dose 0.8 mg/m\^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
Study NCT00770731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (Bortezomib)
Description: Starting Dose 0.3 mg/m\^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin 400 mg
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211 Placebo
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX4211 Placebo
Study NCT01913002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LX4211 Placebo
Study NCT02161991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
Study NCT02161991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
Study NCT01850134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Study Product
Study NCT04039737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingpeng Ointment
Description: Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
Study NCT03332836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HM12460A
Description: HM12460A is a long-acting insulin
Study NCT04428957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Daily telemonitoring of heart rate (HR), blood pressure (BP), pulse oximetry (SpO2), spirometry (FVC), activity (accelerometry) and severity of cough and dyspnea
Study NCT00674414 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Trastuzumab (Herceptin®) IV once weekly
Study NCT00674414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Trastuzumab (Herceptin®) IV once weekly
Study NCT00674414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Oral everolimus once daily
Study NCT00674414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery
Study NCT00674414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Patients undergo surgery
Study NCT04327726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Nebulization
Description: ultrasonic nebulization of 1 µg/kg dexmedetomidine for PDPH treatment
Study NCT04327726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Nebulization
Description: nebulization of 4mL 0.9% saline
Study NCT03567746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Underwater EMR
Description: Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
Study NCT03567746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional EMR
Description: It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
Study NCT01822262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive cholecystolithotomy with gallbladder reservation
Study NCT01822262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic cholecystectomy
Study NCT02641301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sustained release morphine sulfate, 30 mg
Description: A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
Study NCT04505891 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and follow-up
Description: In patients allocated to the education and follow-up arm, education along with a a post-discharge healthcare visit from a multidisciplinary care team will be performed.
Study NCT01262014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
Study NCT02641301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained release morphine sulfate, 30 mg
Description: A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
Study NCT04334460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BLD-2660
Description: BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.
Study NCT04334460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLD-2660
Description: BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.
Study NCT01554449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serious game reeducation
Description: It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
Study NCT01554449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serious game reeducation
Description: It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
Study NCT01554449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: functional MRI
Description: the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
Study NCT01554449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: functional MRI
Description: the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
Study NCT01554449 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: functional MRI
Description: the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
Study NCT01771796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic and muscle resistance training
Description: After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
Study NCT02697318 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Timolol maleate 0.5% ophthalmic solution
Study NCT03458130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG10
Description: TTR stabilizer
Study NCT03458130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Nonactive control
Study NCT04062916 — intervention group
Intervention type: OTHER
Intervention: BSGE pelvic pain questionnaire and VAS scores
Description: Patients were evaluated using the BSGE pelvic pain questionnaire in terms of pre-operative and post-operative pain assessment in order to determine the effects of endometriosis surgery on the quality of life. The patients were asked to indicate their levels of dyspareunia, dysmenorrhea, and chronic pelvic pain on a VAS on the pelvic pain questionnaire.
Study NCT00169650 — intervention group
Intervention type: OTHER
Intervention: Registry and database
Description: Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
Study NCT01327352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi D
Description: oral administration
Study NCT01443247 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: anti-d
Description: intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
Study NCT01443247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-d
Description: intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
Study NCT01020812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Standard of Care
Study NCT04209179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCO371
Description: PCO371 capsule
Study NCT04209179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT01946737 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)
Study NCT01020812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Standard of Care
Study NCT01554618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Once Weekly
Description: 2 mg exenatide once weekly
Study NCT01554618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01946737 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Invasive coronary angiography (ICA)
Study NCT03322410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified Peritoneal Equilibration test
Description: Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~*  High : D/P creatinine>0,8; D/D0 glucose\<0,25~*  High average : 0,65\< D/P creatinine \<0,8; 0,25\< D/D0 glucose \<0,38~*  Low average : 0,5\< D/P creatinine \<0,65; 0,39\< D/D0 glucose \< 0,48~*  Low  : D/P creatinine\<0,5 ; D/D0 glucose>0,49.
Study NCT02709811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Study NCT01873040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media plus information pages
Description: Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
Study NCT01873040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine Information Pages
Description: Participants will receive access to the study vaccine website information pages.
Study NCT00897468 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
Study NCT00897468 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: patient chart review will occur in conjunction with patient data collection for final analyses.
Study NCT05224453 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical training and high protein diet
Description: In addition to the integrated physical training exercises, group A received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d)
Study NCT05224453 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical training and low protein diet
Description: In addition to the integrated physical training exercises, group B received low protein diet in the range of 0.7 - 0.9 g/kg protein/ ideal body weight/day (\<1 g/kg aBW/d)
Study NCT02544919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMOF lipid (SMOFLIPID) pre treatment
Description: Experimental Arm
Study NCT00999440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
Study NCT02253953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D1
Study NCT02253953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D2
Study NCT02253953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D3
Study NCT02253953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS, D4
Study NCT00953849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib (400 mg twice daily)
Study NCT00953849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
Study NCT00953849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib plus Calcitriol
Description: 3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
Study NCT03047408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video polysomnography
Description: the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
Study NCT03247140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1401
Description: Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
Study NCT03247140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine, Rosuvastatin
Description: Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
Study NCT01588873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel
Description: The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment.
Study NCT00250731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone support and behavior change
Description: Diabetes self-management education provided over the telephone either for individuals or couples
Study NCT00250731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telephone support and behavior change
Description: Diabetes self-management education provided over the telephone either for individuals or couples
Study NCT00250731 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diabetes self-management education
Description: Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
Study NCT02335359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid diluted in 100 ml of saline solution (loading dose)
Study NCT02335359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid undiluted (continous infusion)
Study NCT02335359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT02617602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal directed therapy
Description: Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~* decreased heart rate (HR): dobutamine, dopamine;~* normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine.
Study NCT02617602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control